(1)
SOUTH SAN FRANCISCO (dpa-AFX) - Today s Daily Dose brings you news about the clinical hold imposed by the FDA on Larimar s CTI-1601 clinical program; Pieris Pharma teaming up with Roche s Genentech; the upcoming regulatory catalyst of Provention Bio; the possible delay in Travere seeking approval for Sparsentan; and the approval of Taiwan Liposome s Liposomal Amphotericin B injection in India to fight the growing cases of black fungus.
Read on.
1. Larimar Plunges On Double Dose Of Bad News
Shares of Larimar Therapeutics, Inc. (LRMR) took a hit Tuesday, following a double dose of bad news.
The company announced that its CTI-1601 clinical program has been placed on hold by the FDA and that a previously announced private placement financing will be terminated.